Pettyjohn Wood & White Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 1.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 83,689 shares of the biopharmaceutical company’s stock after acquiring an additional 1,085 shares during the period. Pettyjohn Wood & White Inc.’s holdings in Pfizer were worth $3,625,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Evolution Wealth Advisors LLC purchased a new position in Pfizer in the 2nd quarter valued at about $34,000. IMA Wealth Inc. lifted its holdings in Pfizer by 144.5% in the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 477 shares in the last quarter. Winch Advisory Services LLC lifted its holdings in Pfizer by 69.6% in the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 336 shares in the last quarter. Ruggie Capital Group purchased a new position in Pfizer in the 4th quarter valued at about $44,000. Finally, Financial Gravity Wealth Inc. lifted its holdings in Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 257 shares in the last quarter. 71.58% of the stock is currently owned by hedge funds and other institutional investors.
In related news, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total value of $6,753,882.56. Following the transaction, the executive vice president now owns 489,647 shares in the company, valued at $21,588,536.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the completion of the transaction, the insider now owns 80,094 shares in the company, valued at approximately $3,524,136. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the firm posted $0.77 EPS. The company’s revenue was down 1.5% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.8 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be issued a $0.36 dividend. The ex-dividend date is Thursday, August 1st. This represents a $1.44 annualized dividend and a yield of 4.13%. Pfizer’s payout ratio is 48.00%.
A number of research firms have issued reports on PFE. JPMorgan Chase & Co. set a $46.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Monday, July 29th. UBS Group reiterated a “neutral” rating and set a $43.00 price objective on shares of Pfizer in a report on Monday, August 5th. Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Morgan Stanley lowered shares of Pfizer from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $48.00 to $40.00 in a report on Tuesday, July 30th. Finally, Barclays reiterated a “hold” rating and set a $41.00 price objective on shares of Pfizer in a report on Thursday, May 9th. Fourteen analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $46.56.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.